CANbridge Pharmaceuticals Inc. announced that it has appointed Edward Hu as non-executive director of the Board of Directors and member of the Remuneration Committee, replacing Xiao Le, who resigns from the CANbridge Board. The appointment is effective as of July 5, 2022. Edward Hu has deep and varied C-level biopharmaceutical experience, having served as both Co-Chief Executive Officer and Chief Financial Officer at WuXi AppTec before his current position of Vice Chairman, Global Chief Investment Officer, Executive Director, Strategy Committee Member.

Before then, Mr. Hu was Chief Financial Officer and Chief Operating Office at WuXi PharmaTech. Prior to his roles at WuXi, Mr. Hu held multiple senior management roles, culminating in that of Senior Vice President and Chief Operating Officer at Tanox Inc., a NASDAQ-traded public company, which was acquired by Genentech. Prior to that, Mr. Hu served as business planning manager of Biogen Inc, and before then, as senior financial analyst at Merck.

Mr. Hu is currently a non-executive director of CStone Pharmaceuticals. Previously, he also served as non-executive director of WuXi Biologics, as well as a director of Viela Bio Inc, which was acquired by Horizon Therapeutics in March 2021. Mr. Hu has a bachelor's degree in physics from Hangzhou University (currently, Zhejiang University), in Zhejiang province, China.

He also has a master's degree in chemistry and a master's degree in business administration, both from Carnegie Mellon University, in Pittsburgh, Pennsylvania.